Advertisement


Judith Balmaña, MD, PhD, on Metastatic Breast Cancer: Study Results on Lurbinectedin

2016 ESMO Congress

Advertisement

Judith Balmaña, MD, PhD, of Vall d’Hebron University Hospital, discusses the findings of a single-agent phase II trial on the antitumor activity of lurbinectedin in BRCA1/2-associated metastatic breast cancer patients. (Abstract 223O)



Related Videos

Lymphoma

Teresa Calimeri, MD, PhD, on DLBCL: Findings on High-Dose Methotrexate

Teresa Calimeri, MD, PhD, of San Raffaele Hospital, discusses high-dose methotrexate as a CNS prophylaxis, shown to significantly improve outcome in patients with high-risk diffuse large B-cell lymphoma. (Abstract 908O)

Lung Cancer

Giorgio V. Scagliotti, MD, PhD, on ALK-Rearranged NSCLC: Results From the ASCEND-5 Trial

Giorgio V. Scagliotti, MD, PhD, of the University of Torino, discusses study findings on ceritinib vs chemotherapy in patients with advanced ALK-rearranged non-small cell lung cancer previously treated with chemotherapy and crizotinib. (Abstract LBA42)

Kidney Cancer

Alain Ravaud, MD, PhD, on RCC: Results of the S-TRAC Trial

Alain Ravaud, MD, PhD, of Bordeaux University Hospital, discusses phase III findings on sunitinib vs placebo as adjuvant treatment for high-risk renal cell carcinoma after nephrectomy. (Abstract LBA11)

Multiple Myeloma

Katja Weisel, MD, on Multiple Myeloma: Results of the CASTOR Study

Katja Weisel, MD, of the University of Tübingen, discusses study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. (Abstract 906O)

Bladder Cancer

Arjun V. Balar, MD, on Urothelial Cancer: Results From KEYNOTE-052

Arjun V. Balar, MD, of the NYU Perlmutter Cancer Center, discusses preliminary phase II study findings on pembrolizumab as first-line therapy for advanced/unresectable or metastatic urothelial cancer. (Abstract LBA32)

Advertisement

Advertisement




Advertisement